Duchenne Muscular Dystrophy Drugs Market Predicted to Hit US$ 4.00 Billion by 2028

IMARC Group, a leading market research company, has recently releases report titled “Duchenne Muscular Dystrophy Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global Duchenne muscular dystrophy drugs market size, growth, share, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

What is Duchenne Muscular Dystrophy Drugs

Duchenne muscular dystrophy (DMD) is a genetic medical disease characterized by progressive muscle degeneration and weakness. It primarily affects males, typically diagnosed in early childhood, and is caused by a mutation in the dystrophin gene, which leads to the deficiency of the dystrophin protein. It is associated with difficulty walking, standing, and sitting, and speech difficulties, which can result in progressive weakness and loss of the skeletal and heart muscles. It can be treated using various drugs, therapies, and medications, such as steroid medications, antisense oligonucleotide therapy, and gene therapy. DMD drugs enhance cardiac and pulmonary functions in patients by targeting cardiac and skeletal muscles.

How Big Is the Duchenne Muscular Dystrophy Drugs Market

The global Duchenne muscular dystrophy drugs market size reached US$ 2.04 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 4.00 Billion by 2028, exhibiting a growth rate (CAGR) of 11.41% during 2023-2028.

Types of Duchenne Muscular Dystrophy Drugs

Duchenne muscular dystrophy (DMD) drugs encompass different types of treatments and therapies for individuals with DMD:

1. Steroids: Commonly prescribed corticosteroids like prednisone and deflazacort are used to alleviate inflammation and slow down muscle degeneration. These drugs aim to enhance muscle strength and function.

2. Gene-based therapies: Emerging therapies focus on addressing the genetic cause of DMD. This includes innovative approaches like gene replacement therapies, such as exon skipping and gene editing, which aim to restore the production of the dystrophin protein that is lacking in individuals with DMD.

3. Supportive therapies: These therapies are designed to manage the symptoms and complications associated with DMD. They encompass various approaches like respiratory support, physical therapy, occupational therapy, and cardiac management.

4. Emerging therapies: Ongoing research and development efforts are aimed at identifying new treatments for DMD. This includes investigational drugs and therapies that target specific pathways involved in the progression of the disease.

What are the Causes of Duchenne Muscular Dystrophy Drugs

Duchenne muscular dystrophy (DMD) primarily stems from genetic mutations that disrupt the production of a vital protein known as dystrophin. This protein’s production is governed by a gene located on the X chromosome. In most instances, DMD follows an X-linked recessive inheritance pattern, making it predominantly afflict males. The most prevalent cause of DMD involves mutations within the DMD gene, which lead to a deficiency or absence of dystrophin. Dystrophin is essential for upholding the structural integrity of muscle cells. In the absence of sufficient dystrophin, muscle fibers become fragile and prone to damage, resulting in the gradual muscle weakness and degeneration characteristic of DMD. These mutations can arise spontaneously during embryo development or be inherited from a carrier mother. Females carrying a single copy of the mutated gene typically remain unaffected or may display milder symptoms due to the presence of a second intact copy of the gene on their other X chromosome. Nonetheless, they possess a 50% chance of passing the mutated gene to their offspring.

What Are the Growth Prospects and Trends in The Duchenne Muscular Dystrophy Drugs Industry?

The rising number of new product approvals and launches by leading manufacturers is among the key factors stimulating the Duchenne muscular dystrophy drugs market. Moreover, the increasing incidences of DMD among individuals are acting as significant growth-inducing factors. Besides this, the inflating clinical trials and the wide presence of a strong pipeline of medications are positively influencing the global market. Furthermore, the introduction of mutation-specific therapies, owing to the continuous innovations in diagnostics, is propelling the market growth. Apart from this, extensive R&D activities focusing on accurate diagnosis and treatment of Duchenne muscular dystrophy for underserved categories, such as infants, females, and non-ambulant patients, are further catalyzing the global market. Additionally, the launch of favorable initiatives by government bodies to provide reimbursement policies and promote target-specific treatments is also augmenting the market growth. In line with this, the expanding medical infrastructures, the emerging trend of product premiumization, and the growing disposable income levels of consumers are anticipated to fuel the Duchenne muscular dystrophy drugs market over the forecasted period.

Top Key Companies Involved in Duchenne Muscular Dystrophy Drugs Industry

• FibroGen Inc.

• Italfarmaco S.p.A.

• NS Pharma Inc. (Nippon Shinyaku Co. Ltd.)

• PTC Therapeutics Inc.

• Santhera Pharmaceuticals

• Sarepta Therapeutics Inc.